04:01 AM EDT, 05/31/2024 (MT Newswires) -- Galapagos (GLPG) and Adaptimmune Therapeutics ( ADAP ) have entered into a clinical collaboration deal to evaluate the safety and efficacy of Adaptimmune's uza-cel in head and neck cancer using Galapagos' decentralized cell manufacturing platform, the companies said late Thursday.

Under the deal, Adaptimmune will receive $100 million in initial payments, consisting of $70 million upfront and $30 million for

research and development, as well as $100 million in potential option exercise fees, and a potential up to $465 million in milestone payments, they said.

Galapagos, on the other hand, receives an exclusive option to license the drug for head-and-neck cancer, and other potential future indications for a maximum of $100 million.

Adaptimmune retains rights to the drug for platinum-resistant ovarian cancer.